[{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"2487ddb2-7738-4021-b64c-94036379e85b","acronym":"CHAMP","url":"https://clinicaltrials.gov/study/NCT04709276","created_at":"2021-01-19T20:52:08.240Z","updated_at":"2025-02-25T14:29:51.192Z","phase":"Phase 2","brief_title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04709276 - CHAMP","lead_sponsor":"Andrew J. Armstrong, MD","biomarkers":" TP53 • PTEN • RB1 • SYP","pipe":" | ","alterations":" LDH elevation","tags":["TP53 • PTEN • RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-14"},{"id":"35c5e79b-54b0-43e1-b61a-1b50d58d242e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06725173","created_at":"2025-02-25T14:43:58.802Z","updated_at":"2025-02-25T14:43:58.802Z","phase":"","brief_title":"Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.","source_id_and_acronym":"NCT06725173","lead_sponsor":"University of Washington","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-02-14"},{"id":"21e02173-6a70-45fc-8771-2545b671be82","acronym":"NCI-2018-01071","url":"https://clinicaltrials.gov/study/NCT03263650","created_at":"2021-01-18T16:07:22.101Z","updated_at":"2025-02-25T14:58:18.982Z","phase":"Phase 2","brief_title":"Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men with AVPC","source_id_and_acronym":"NCT03263650 - NCI-2018-01071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1 • CEACAM5","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-05"},{"id":"11c83591-4e3f-4858-aa5c-0d9de1fd1c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691465","created_at":"2023-01-20T16:00:13.319Z","updated_at":"2025-02-25T16:54:41.696Z","phase":"Phase 2","brief_title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","source_id_and_acronym":"NCT05691465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • RB1 • SYP • CHGA","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/27/2023","start_date":" 12/27/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-04"},{"id":"9eb44888-36d6-498e-87f2-66cdcbe3ea1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02099864","created_at":"2021-01-17T17:57:53.255Z","updated_at":"2025-02-25T15:33:07.009Z","phase":"Phase 2","brief_title":"Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy","source_id_and_acronym":"NCT02099864","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • PTEN • AR • RB1","pipe":" | ","alterations":" PTEN mutation • AR splice variant 7","tags":["TP53 • PTEN • AR • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/05/2014","start_date":" 02/05/2014","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-09-19"},{"id":"aa92e647-2204-49a9-b0eb-03d672654c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05037500","created_at":"2021-09-08T14:53:05.286Z","updated_at":"2024-07-02T16:34:27.381Z","phase":"Phase 1","brief_title":"Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT05037500","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" TP53 • RB1","pipe":"","alterations":" ","tags":["TP53 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-11"},{"id":"ccfd455c-e774-4e0e-bb52-ee525cf236c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592237","created_at":"2021-01-19T20:28:42.436Z","updated_at":"2024-07-02T16:34:58.883Z","phase":"Phase 2","brief_title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04592237","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1 • CEACAM5","pipe":" | ","alterations":" PTEN mutation","tags":["PD-L1 • TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-04"},{"id":"bec56339-c58d-4adf-b9c5-7c33103ad8b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05694871","created_at":"2023-01-23T14:59:43.962Z","updated_at":"2024-07-02T16:35:01.360Z","phase":"Phase 2","brief_title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05694871","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • RB1 • CDK4","pipe":" | ","alterations":" PD-L1 expression • RB1 mutation","tags":["PD-L1 • RB1 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-05-23"},{"id":"1ba7d423-e8de-4bf4-9f12-f7ec8c7c5db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03526250","created_at":"2021-01-18T17:22:05.437Z","updated_at":"2024-07-02T16:35:02.332Z","phase":"Phase 2","brief_title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03526250","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-21"},{"id":"f7eb27f3-8b9e-4d94-9852-c62cefd66a29","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388852","created_at":"2021-01-18T21:11:08.040Z","updated_at":"2024-07-02T16:35:03.232Z","phase":"Phase 1","brief_title":"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers","source_id_and_acronym":"NCT04388852","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1","pipe":"","alterations":" ","tags":["PD-L1 • TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/20/2020","start_date":" 08/20/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-16"},{"id":"a532ecf0-a3c8-400f-b42b-9187fc8e7481","acronym":"RIVERBOAT","url":"https://clinicaltrials.gov/study/NCT03932786","created_at":"2021-01-18T19:22:16.373Z","updated_at":"2024-07-02T16:35:04.323Z","phase":"","brief_title":"Studying Health Outcomes After Treatment in Patients With Retinoblastoma","source_id_and_acronym":"NCT03932786 - RIVERBOAT","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-05-10"},{"id":"c84d8944-d78f-409a-b988-e7289ade4c23","acronym":"FIRST-NEC","url":"https://clinicaltrials.gov/study/NCT06393816","created_at":"2024-05-04T04:28:40.403Z","updated_at":"2024-07-02T16:35:05.677Z","phase":"Phase 2","brief_title":"FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum","source_id_and_acronym":"NCT06393816 - FIRST-NEC","lead_sponsor":"Centre Leon Berard","biomarkers":" PD-L1 • RB1","pipe":" | ","alterations":" PD-L1 expression • RB1 mutation","tags":["PD-L1 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-05-06"},{"id":"447deee0-48df-4d5d-a0f4-8e3810a39c90","acronym":"DepiSCARRH","url":"https://clinicaltrials.gov/study/NCT03026998","created_at":"2021-01-18T14:53:55.583Z","updated_at":"2024-07-02T16:35:06.766Z","phase":"","brief_title":"MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)","source_id_and_acronym":"NCT03026998 - DepiSCARRH","lead_sponsor":"Institut Curie","biomarkers":" RB1","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 03/19/2017","start_date":" 03/19/2017","primary_txt":" Primary completion: 03/01/2034","primary_completion_date":" 03/01/2034","study_txt":" Completion: 03/01/2034","study_completion_date":" 03/01/2034","last_update_posted":"2024-04-30"},{"id":"70736adb-b060-44c5-baf0-08a2f859c924","acronym":"","url":"https://clinicaltrials.gov/study/NCT04471974","created_at":"2021-01-18T21:29:11.594Z","updated_at":"2025-02-25T16:10:30.954Z","phase":"Phase 2","brief_title":"ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04471974","lead_sponsor":"Rahul Aggarwal","biomarkers":" PD-L1 • RB1","pipe":" | ","alterations":" RB1 deletion • RB deletion","tags":["PD-L1 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xtandi (enzalutamide) • ZEN-3694 • ZEN-3219"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-04-26"},{"id":"ee1f7ecf-9bc4-4111-8b8a-fd3789290137","acronym":"","url":"https://clinicaltrials.gov/study/NCT04926181","created_at":"2021-06-15T17:53:11.788Z","updated_at":"2024-07-02T16:35:07.351Z","phase":"Phase 2","brief_title":"Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer","source_id_and_acronym":"NCT04926181","lead_sponsor":"Rahul Aggarwal","biomarkers":" RB1 • SYP","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-04-26"},{"id":"d4abf529-67b2-46e8-a739-11f0991f275a","acronym":"RTB","url":"https://clinicaltrials.gov/study/NCT03284268","created_at":"2021-01-18T16:13:30.310Z","updated_at":"2024-07-02T16:35:08.341Z","phase":"","brief_title":"Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","source_id_and_acronym":"NCT03284268 - RTB","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"fbf4520a-0024-4ad4-aacb-7c70b6344b99","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074785","created_at":"2021-01-18T19:57:29.190Z","updated_at":"2024-07-02T16:35:08.254Z","phase":"Phase 1","brief_title":"Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6","source_id_and_acronym":"NCT04074785","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • RB1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/13/2019","start_date":" 12/13/2019","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 10/24/2025","study_completion_date":" 10/24/2025","last_update_posted":"2024-04-22"},{"id":"ae2fbbdf-1d9d-47eb-9888-dad360517475","acronym":"MATRIX","url":"https://clinicaltrials.gov/study/NCT05986071","created_at":"2023-08-14T15:09:50.416Z","updated_at":"2025-02-25T16:19:00.084Z","phase":"Phase 1/2","brief_title":"I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","source_id_and_acronym":"NCT05986071 - MATRIX","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1","pipe":" | ","alterations":" HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • tuvusertib (M1774)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/15/2027","study_completion_date":" 10/15/2027","last_update_posted":"2024-03-29"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"2a4bf351-5891-4378-a18a-58000cb4e271","acronym":"","url":"https://clinicaltrials.gov/study/NCT00342797","created_at":"2021-01-18T01:11:06.648Z","updated_at":"2024-07-02T16:35:15.944Z","phase":"","brief_title":"Retinoblastoma Biomarker Study","source_id_and_acronym":"NCT00342797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 2136","initiation":"Initiation: 11/17/1993","start_date":" 11/17/1993","primary_txt":" Primary completion: 03/06/2024","primary_completion_date":" 03/06/2024","study_txt":" Completion: 03/06/2024","study_completion_date":" 03/06/2024","last_update_posted":"2024-03-07"},{"id":"366da270-8f09-44d6-be12-90adac16a8b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085729","created_at":"2023-10-17T15:12:33.301Z","updated_at":"2024-07-02T16:35:16.807Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","source_id_and_acronym":"NCT06085729","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • PTEN mutation • LDH elevation","tags":["TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PTEN mutation • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-01"}]